Focal Medical, Inc.
Raleigh, NC · CIK 0001831601 · Medtech · Acquired
Implantable iontophoresis device for direct chemotherapy delivery into tumors
focalmedical.co →- Grants
- $8.2M
- 6 awards
- Sector median: 1
- Raised
- $6.4M
- 2 Form D · Mar 2024
- 31 months since last filing
- Contracts
- $298K
- 1 award · Health and Human S
- #425 of 4531 in medtech
- Patents
- 6
- 0 granted · 6 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172018201920202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial | $299,805 | |
| Federal grant | Department of Health and Human Services · Phase II · Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial | $1,111,364 | |
| Federal grant | Department of Health and Human Services · Phase II · Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial | $2,084 | |
| Federal grant | Department of Health and Human Services · Phase II · Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial | $771,376 | |
| Private capital raised | Form D · SEC | $5,499,993 | |
| Federal grant | Department of Health and Human Services · Phase II · Implantable iontophoresis chemotherapy delivery device for direct infusion ofgemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial | $4,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Implantable iontophoresis chemotherapy delivery device for direct infusion ofgemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial | $2,000,000 | |
| Federal contract | Department of Health and Human Services · 2024 SBIR Concept Clearance Award | $297,965 | |
| Private capital raised | Form D · SEC | $950,000 |
Federal grant · SBIR/STTRFederal contract · USAspendingForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 422 | DARWIN BIOSCIENCES, INC. | $299K | — |
| 423 | SEVIDENT, INC. | $299K | — |
| 424 | SALUS DISCOVERY LLC | $299K | — |
| 425 | Focal Medical, Inc. | $298K | $6.4M |
| 426 | MGENUITY CORPORATION | $296K | — |
| 427 | Koronis Biomedical Technologies Corp. | $296K | — |
| 428 | ACOUSTICABIO, INC. | $295K | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Michael AldridgeDirector · Executive Officer
- Nessan BerminghamDirector
- Joseph DeSimoneDirector
- Anthony VoiersDirector · Executive Officer · Promoter
- Jen Jen YehDirector
Patents
- System And Method For Electroporationapplication
- Tissue ablation guided by electrical impedance spectroscopyapplication
- Delivery Of Chemotherapy Drug Via An Implantable Iontophoresis Drug Delivery Deviceapplication
- DELIVERY OF mRNA BY IONTOPHORESISapplication
- Implantable Reservoir For Use With A Medical Device And System For Interventional Drug Deliveryapplication
- Delivery of Gemcitabine Hydrochloride via an Implantable Iontophoresis Drug Delivery Deviceapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.